Business
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe
SHANGHAI, China & JERSEY CITY, N.J., April 29, 2026--European Commission approves Henlius and Organon’s POHERDY® (pertuzumab), the first approved Biosimilar to PERJETA (pertuzumab) in Europe
About this update from Organon & Co.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2100,"height":315,"url":"https://media.zenfs.com/en/business-wire.com/5b56a65687299d63c605fd32b8a6a295"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PB4vh82Zryll7zoEv1ogYQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE0NA--/https://media.zenfs.com/en/business-wire.com/5b56a65687299d63c605fd32b8a6a295","width":960,"height":144},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/dKomII87YUeQkt1mcIWfjA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zNjA-/https://media.zenfs.com/en/business-wire.com/5b56a65687299d63c605fd32b8a6a295","width":1200,"height":180}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":209,"url":"https://media.zenfs.com/en/business-wire.com/7d98bd91a344722be01c8f4315623110"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7ylWeA6YZbvA5Y0iBeJ.Pw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQxOA--/https://media.zenfs.com/en/business-wire.com/7d98bd91a344722be01c8f4315623110","width":480,"height":209}}},{"type":"text","content":"SHANGHAI, China & JERSEY CITY, N.J., April 29, 2026--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1","length":411,"tagName":"p"},{"type":"text","content":""As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union," said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 "Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of health care systems while advancing women’s health through access to quality medicines."3,4","length":642,"tagName":"p"},{"type":"text","conten...